260 related articles for article (PubMed ID: 19619690)
1. Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study.
Pratt CM; Reiffel JA; Ellenbogen KA; Naccarelli GV; Kowey PR
Am Heart J; 2009 Aug; 158(2):163-169.e1-3. PubMed ID: 19619690
[TBL] [Abstract][Full Text] [Related]
2. The rationale and design of the FORomegaARD Trial: A randomized, double-blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation.
Macchia A; Varini S; Grancelli H; Nul D; Laffaye N; Ferrante D; Tognoni G; Doval HC;
Am Heart J; 2009 Mar; 157(3):423-7. PubMed ID: 19249410
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial.
Kowey PR; Reiffel JA; Ellenbogen KA; Naccarelli GV; Pratt CM
JAMA; 2010 Dec; 304(21):2363-72. PubMed ID: 21078810
[TBL] [Abstract][Full Text] [Related]
5. Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.
Rupp H
Adv Ther; 2009 Jul; 26(7):675-90. PubMed ID: 19629408
[TBL] [Abstract][Full Text] [Related]
6. n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study.
Bianconi L; Calò L; Mennuni M; Santini L; Morosetti P; Azzolini P; Barbato G; Biscione F; Romano P; Santini M
Europace; 2011 Feb; 13(2):174-81. PubMed ID: 21059740
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter.
Hohnloser SH; Connolly SJ; Crijns HJ; Page RL; Seiz W; Torp-Petersen C
J Cardiovasc Electrophysiol; 2008 Jan; 19(1):69-73. PubMed ID: 18031520
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of a randomized clinical trial to assess the role of overdrive and triggered prevention pacing therapies in reducing atrial fibrillation: the Study of Atrial Fibrillation Reduction (SAFARI).
Gold MR; Hoffmann E;
Am Heart J; 2006 Aug; 152(2):231-6. PubMed ID: 16875902
[TBL] [Abstract][Full Text] [Related]
9. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.
Roy D; Rowe BH; Stiell IG; Coutu B; Ip JH; Phaneuf D; Lee J; Vidaillet H; Dickinson G; Grant S; Ezrin AM; Beatch GN;
J Am Coll Cardiol; 2004 Dec; 44(12):2355-61. PubMed ID: 15607398
[TBL] [Abstract][Full Text] [Related]
10. Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients.
Kirkegaard E; Svensson M; Strandhave C; Schmidt EB; Jørgensen KA; Christensen JH
Br J Nutr; 2012 Mar; 107(6):903-9. PubMed ID: 21791142
[TBL] [Abstract][Full Text] [Related]
11. Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial.
Kirchhof P; Fetsch T; Hanrath P; Meinertz T; Steinbeck G; Lehmacher W; Breithardt G
Am Heart J; 2005 Nov; 150(5):899. PubMed ID: 16290956
[TBL] [Abstract][Full Text] [Related]
12. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.
Connolly SJ; Crijns HJ; Torp-Pedersen C; van Eickels M; Gaudin C; Page RL; Hohnloser SH;
Circulation; 2009 Sep; 120(13):1174-80. PubMed ID: 19752319
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.
Goette A; Schön N; Kirchhof P; Breithardt G; Fetsch T; Häusler KG; Klein HU; Steinbeck G; Wegscheider K; Meinertz T
Circ Arrhythm Electrophysiol; 2012 Feb; 5(1):43-51. PubMed ID: 22157519
[TBL] [Abstract][Full Text] [Related]
14. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial.
Macchia A; Grancelli H; Varini S; Nul D; Laffaye N; Mariani J; Ferrante D; Badra R; Figal J; Ramos S; Tognoni G; Doval HC;
J Am Coll Cardiol; 2013 Jan; 61(4):463-468. PubMed ID: 23265344
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
Disertori M; Latini R; Maggioni AP; Delise P; Di Pasquale G; Franzosi MG; Staszewsky L; Tognoni G;
J Cardiovasc Med (Hagerstown); 2006 Jan; 7(1):29-38. PubMed ID: 16645357
[TBL] [Abstract][Full Text] [Related]
16. Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: the PITAGORA trial.
Gulizia M; Mangiameli S; Chiarandà G; Spadola V; Di Giovanni N; Colletti A; Bulla V; Circo A; Pensabene O; Vasquez L; Vaccaro I; Grammatico A;
Europace; 2006 Apr; 8(4):302-5. PubMed ID: 16627459
[TBL] [Abstract][Full Text] [Related]
17. Right atrial preventive and antitachycardia pacing for prevention of paroxysmal atrial fibrillation in patients without bradycardia: a randomized study.
Hemels ME; Ruiter JH; Molhoek GP; Veeger NJ; Wiesfeld AC; Ranchor AV; van Trigt M; Pilmeyer A; Van Gelder IC; ;
Europace; 2008 Mar; 10(3):306-13. PubMed ID: 18245199
[TBL] [Abstract][Full Text] [Related]
18. Conventional and dedicated atrial overdrive pacing for the prevention of paroxysmal atrial fibrillation: the AFTherapy study.
Camm AJ; Sulke N; Edvardsson N; Ritter P; Albers BA; Ruiter JH; Lewalter T; Capucci PA; Hoffmann E;
Europace; 2007 Dec; 9(12):1110-8. PubMed ID: 18042619
[TBL] [Abstract][Full Text] [Related]
19. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy.
Singh SN; Tang XC; Singh BN; Dorian P; Reda DJ; Harris CL; Fletcher RD; Sharma SC; Atwood JE; Jacobson AK; Lewis HD; Lopez B; Raisch DW; Ezekowitz MD;
J Am Coll Cardiol; 2006 Aug; 48(4):721-30. PubMed ID: 16904540
[TBL] [Abstract][Full Text] [Related]
20. Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis.
Burgess DC; Kilborn MJ; Keech AC
Eur Heart J; 2006 Dec; 27(23):2846-57. PubMed ID: 17015402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
